March 18th 2024
From our March cover feature: Vulnerable populations such as the prison population should have access to Mohs surgery to prevent the increased risk of morbidity and mortality from skin cancer.
The Science Behind Using Circulating Tumor DNA for MCC
March 31st 2022In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult MCC
March 30th 2022In this first part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the science behind her presentation on "The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult Merkel Cell Carcinoma." This was presented at the 2022 American Academy of Dermatology Annual Meeting.
Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma
September 16th 2021The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.
SRT Shows Positive Outcomes for NMSC
August 25th 2021Part 1 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting in Nashville, Tennessee, showcases this therapy’s efficacy in treating keratinocytic skin cancers.